Cargando…
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
BACKGROUND: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP). METHODS: Of 60 patients with a mean BP of 173.3 ± 1.7/9...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792946/ https://www.ncbi.nlm.nih.gov/pubmed/24109189 http://dx.doi.org/10.2147/VHRM.S44568 |
_version_ | 1782286905346359296 |
---|---|
author | Radchenko, GD Sirenko, YM Kushnir, SM Torbas, OO Dobrokhod, AS |
author_facet | Radchenko, GD Sirenko, YM Kushnir, SM Torbas, OO Dobrokhod, AS |
author_sort | Radchenko, GD |
collection | PubMed |
description | BACKGROUND: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP). METHODS: Of 60 patients with a mean BP of 173.3 ± 1.7/98.4 ± 1.2 mmHg, 59 were random-ized to losartan + HCTZ (n = 32) or bisoprolol + HCTZ (n = 27). Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months. Body mass index, office and 24-hour ambulatory BP, pulse wave velocity (carotid-femoral [PWVE] and radial [PWVM]), noninvasive central systolic BP, augmentation index (AIx), laboratory investigations, and electrocardiography were done at baseline and after 6 months of treatment. RESULTS: Losartan + HCTZ was as effective as bisoprolol + HCTZ, with target office BP achieved in 96.9% and 92.6% of patients and target 24-hour BP in 75% and 66.7% of patients, respectively, after 6 months. Effective treatment of BP led to significant lowering of central systolic BP, but this was decreased to a significantly (P < 0.05) greater extent by losartan + HCTZ (−23.0 ± 2.3 mmHg) than by bisoprolol + HCTZ (−15.4 ± 2.9 mmHg) despite equal lowering of brachial BP. Factors correlated with central systolic BP and its lowering differed between the treatment groups. Losartan + HCTZ did not alter arterial stiffness patterns significantly, but bisoprolol + HCTZ significantly increased AIx. We noted differences in ΔPWVE, ΔPWVM, and ΔAIx between the groups in favor of losartan + HCTZ. Decreased heart rate was associated with higher central systolic BP and AIx in the bisoprolol + HCTZ group, but was not associated with increased AIx in the losartan + HCTZ group. CONCLUSION: Although both treatments decreased both office and 24-hour BP, losartan + HCTZ significantly decreased central systolic BP and had a more positive influence on pulse wave velocity, with a less negative effect of decreased heart rate on AIx and central systolic BP. |
format | Online Article Text |
id | pubmed-3792946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-37929462013-10-09 Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial Radchenko, GD Sirenko, YM Kushnir, SM Torbas, OO Dobrokhod, AS Vasc Health Risk Manag Original Research BACKGROUND: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP). METHODS: Of 60 patients with a mean BP of 173.3 ± 1.7/98.4 ± 1.2 mmHg, 59 were random-ized to losartan + HCTZ (n = 32) or bisoprolol + HCTZ (n = 27). Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months. Body mass index, office and 24-hour ambulatory BP, pulse wave velocity (carotid-femoral [PWVE] and radial [PWVM]), noninvasive central systolic BP, augmentation index (AIx), laboratory investigations, and electrocardiography were done at baseline and after 6 months of treatment. RESULTS: Losartan + HCTZ was as effective as bisoprolol + HCTZ, with target office BP achieved in 96.9% and 92.6% of patients and target 24-hour BP in 75% and 66.7% of patients, respectively, after 6 months. Effective treatment of BP led to significant lowering of central systolic BP, but this was decreased to a significantly (P < 0.05) greater extent by losartan + HCTZ (−23.0 ± 2.3 mmHg) than by bisoprolol + HCTZ (−15.4 ± 2.9 mmHg) despite equal lowering of brachial BP. Factors correlated with central systolic BP and its lowering differed between the treatment groups. Losartan + HCTZ did not alter arterial stiffness patterns significantly, but bisoprolol + HCTZ significantly increased AIx. We noted differences in ΔPWVE, ΔPWVM, and ΔAIx between the groups in favor of losartan + HCTZ. Decreased heart rate was associated with higher central systolic BP and AIx in the bisoprolol + HCTZ group, but was not associated with increased AIx in the losartan + HCTZ group. CONCLUSION: Although both treatments decreased both office and 24-hour BP, losartan + HCTZ significantly decreased central systolic BP and had a more positive influence on pulse wave velocity, with a less negative effect of decreased heart rate on AIx and central systolic BP. Dove Medical Press 2013 2013-09-27 /pmc/articles/PMC3792946/ /pubmed/24109189 http://dx.doi.org/10.2147/VHRM.S44568 Text en © 2013 Radchenko et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Radchenko, GD Sirenko, YM Kushnir, SM Torbas, OO Dobrokhod, AS Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial |
title | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial |
title_full | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial |
title_fullStr | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial |
title_full_unstemmed | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial |
title_short | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial |
title_sort | comparative effectiveness of a fixed-dose combination of losartan + hctz versus bisoprolol + hctz in patients with moderate-to-severe hypertension: results of the 6-month eliza trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792946/ https://www.ncbi.nlm.nih.gov/pubmed/24109189 http://dx.doi.org/10.2147/VHRM.S44568 |
work_keys_str_mv | AT radchenkogd comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial AT sirenkoym comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial AT kushnirsm comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial AT torbasoo comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial AT dobrokhodas comparativeeffectivenessofafixeddosecombinationoflosartanhctzversusbisoprololhctzinpatientswithmoderatetoseverehypertensionresultsofthe6monthelizatrial |